BG
RCUS icon

Bellevue Group’s Arcus Biosciences RCUS Stock Holding History

Bellevue Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-65,864
Closed -$1.36M – 171
2022
Q4 		$1.36M Sell
65,864
-17,636
-21% -$485K 0.02% 132
2022
Q3 		$2.18M Sell
83,500
-6,600
-7% -$175K 0.03% 122
2022
Q2 		$2.28M Sell
90,100
-21,600
-19% -$529K 0.03% 126
2022
Q1 		$3.52M Buy
111,700
+24,200
+28% +$811K 0.04% 125
2021
Q4 		$3.54M Sell
87,500
-7,200
-8% -$279K 0.04% 132
2021
Q3 		$3.3M Buy
94,700
+19,700
+26% +$613K 0.03% 140
2021
Q2 		$2.06M Hold
75,000
– – 0.02% 141
2021
Q1 		$2.11M Buy
75,000
+24,000
+47% +$835K 0.02% 140
2020
Q4 		$1.32M Buy
+51,000
New +$1.23M 0.02% 152

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bellevue Group's RCUS Position: Q1 2023 in Review

Bellevue Group sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 65,864 shares — an estimated $1.36M sold.

Bellevue Group first reported a position in RCUS in Q4 2020 and held it in 9 quarters. The position peaked at $3.54M in Q4 2021. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

  • Bellevue Group reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
  • Bellevue Group sold 65,864 Arcus Biosciences shares in Q1 2023, an estimated $1.36M.
  • Bellevue Group first reported a position in Arcus Biosciences in Q4 2020 and held it in 9 quarters.
  • Bellevue Group's Arcus Biosciences position peaked at $3.54M in Q4 2021.
  • 179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.